Covid-19: Handling of Marketing Authorisations
Recommendation
20 October 2026
Copenhagen, Denmark
An ECA Course prior to the 29th APIC/CEFIC Global GMP & Regulatory API Conference
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The processes and procedures relating to marketing authorisations are still strongly influenced by the corona pandemic. On the website of the HMA (Heads of Medicines Agencies) this has been reiterated and the available templates and information to facilitate and manage marketing authorisations and registration procedures have been consolidated and listed.
In addition to the continuously updated catalogue"QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC", the "Template for submission of an application for a Covid-19 exeptional change management process (ECMP)" and the "Template for Step 3 Notification of implementation" are available here.
The overview of the information provided and application templates can be found on the website of the HMA (Heads of Medicines Agencies) in the section CMDh.
Related GMP News
14.10.2026Bioassays in the United States Pharmacopoeia - Two Chapters come into Force in Spring
14.10.2026EDQM Revises Guidance on Electronic Submissions for CEP Applications
07.10.2026CEP 2.0: EDQM Updates Guidance on the Use of Certificates of Suitability
07.10.2026EDQM Updates Guidance on CEP Sister File Applications
23.09.2026IRIS Portal: EMA expands digital Procedure Management
16.09.2026EMA updates Procedural Guidance for Application Preparation